Kornimate/medical-research-clean huggingface dataset:
study of sleep habits and prevalence of sleepiness in a health care environment in barcelona

Conditions: Sleep; Subjective Sleepiness; Sleep Apnea

Summary: the purpose of this study is the description of sleeping habits in a working population in the investigators health care environment, analyzing the prevalence of daytime sleepiness and symptoms compatible with the sleep apnea syndrome and finally to analyze predictors of daytime sleepiness.

descriptive study population in a working population in a tertiary hospital in barcelona (spain). the population will consist of subjects who come to the annual medical checkups at the hospital. exclusion criteria: pregnant women. assuming a prevalence of excessive daytime sleepiness of 20 ± 5% with a confidence interval of 95% the number of subjects to be studied is 500. methods: 1. general information and anthropometric data 2. questionnaires 2.1. general questionnaire, working schedules and anthropometric data 2.2. sleeping habits questionnaire 2.3. frequency of perceived daytime sleepiness (5 item questionnaire(kim h, young t.sleep 2005;28:625-634) 1. not rested during the day no matter how many hours of sleep you had 2. feeling of excessive daytime sleepiness 0.71† 0.08 0.03 3. great difficulty getting up in the morning 0.62† -0.06 -0.05 4. need for coffee, or other stimulants to stay awake during the day 5. falling asleep or dozing momentarily at meetings, church, etc. (item responses (frequency per month): 0=never, 1=rarely (once), 2= sometimes(2-4), 3 (often (5-15), 4=almost always (16-30) 2.4. epworth sleepiness scale 2.5. berlin questionnaire questionnaires will be answered in an anonymous and voluntary way on the part of workers. data analysis: 1. general and anthropometric data (mean and standard deviation) 2. sleep habits: sleep latency, sleep time (night and 24 hours), satisfaction with sleep, sleep-debt, anxiolytic medication before bedtime 3. prevalence of daytime sleepiness: * daytime sleepiness questionnaire, consisting of five items coded on a 0-4 ordinal scale (range 00-20 final score). * epworth sleepiness scale: range 0-24, being a value ≥ 10 indicative of daytime sleepiness. * association between daytime sleepiness, anthropometric variables, and variables derived from sleeping habits questionnaire. 4. prevalence of traffic accidents in itinera, and their association with daytime sleepiness, shift work or sleep apnea symptoms. 5. berlin questionnaire: - category 1 positive with 2 or more positive answers to questions 2-6 - category 2 positive with 2 or more positive answers to questions 7-9 - category 3 positive response with a positive and / or a bmi\> 30 or more positive categories indicates a high probability of sleep apnea syndrome.

Eligibility criteria:
inclusion criteria: * workers attending annual checkups at the hospital's medical department. exclusion criteria: * pregnant women

Keywords: sleep sleep apnea work sleep habits sleepiness
the evaluation of white matter intensities in patients with pediatric epilepsy

Conditions: Epilepsies; White Matter Alterations

Summary: aim: neuroimaging is an important tool, in combination with a detailed medical history, physical examination, and electroencephalography, in the diagnosis and classification of epilepsy. white matter hyperintensities (wmhs) are bright areas of high signal intensity seen in white matter at t2-weighted mri. researchers aimed to evaluate whether white matter hyperintensities are more common in children with epilepsy. material-method: patients who underwent cranial mri with diagnoses of epilepsy based on international league against epilepsy (ilae) criteria at the balıkesir university medical faculty pediatric neurology clinic, türkiye, between 01.08.2019 and 01.03.2024 and patients who underwent cranial mri during the same period due to indications other than epilepsy, such as headache, syncope, and vertigo, were included in the study. written informed consent was received from all patients.

aim: neuroimaging is an important tool, in combination with a detailed medical history, physical examination, and electroencephalography, in the diagnosis and classification of epilepsy. white matter hyperintensities (wmhs) are bright areas of high signal intensity seen in white matter at t2-weighted mri. researchers aimed to evaluate whether white matter hyperintensities are more common in children with epilepsy. material-method: patients who underwent cranial mri with diagnoses of epilepsy based on international league against epilepsy (ilae) criteria at the balıkesir university medical faculty pediatric neurology clinic, türkiye, between 01.08.2019 and 01.03.2024 and patients who underwent cranial mri during the same period due to indications other than epilepsy, such as headache, syncope, and vertigo, were included in the study. written informed consent was received from all patients.

Eligibility criteria:
inclusion criteria: cranial mri during the same period due to indications other than epilepsy; * headache * syncope and * vertigo exclusion criteria: patients with neuropsychiatric disorders; * depression, * psychotic disorders, * autism spectrum disorder history of medication use for any chronic disease other than seizure medication, history of vascular disease ; * collagen tissue diseases; * lupus, * juvenile rheumatoid arthritis, * polyarteritis nodosa, * kawasaki disease demyelinating disease * acute demyelinating disease (adem), * multiple sclerosis acute symptomatic seizure or a single unprovoked seizure, i̇ncomplete file data, or mri performed at a location other than our hospital

Keywords: children epilepsy white matter hyperintensity
evaluation of the quality of cardio-pulmonary resuscitation (cpr) in cardiac arrest patients

Conditions: Cardiac Arrest

Summary: the prognosis of cardiac arrest patients is generally poor. recent studies have showed that the high quality of cpr increases the survival after cardiac arrest. therefore the investigators planned this prospective observational study to determine the epidemiology of sudden cardiac arrest in the prehospital setting of tampere area, the quality of the cpr, and also the associations between depth and frequency of chest compressions and invasive arterial pressure, etco2,cerebral oxygenation and iatrogenic injuries associated to chest compressions 1) in patients resuscitated out of hospital by emergency medical service's (ems's) personals and 2) in-hospital by hospital resuscitation team members. in addition, the investigators will analyze the effects of the chosen method of resuscitation on critical vital signs (etco2 and invasive pressures): closed-chest cpr is compared to open-chest cpr, or mechanical cpr with a device (autopulse-cpr, cardio pump) compared to manual cpr guided with quality cpr device. the results will give the investigators important insights into the haemodynamics of cpr which may guide future strategies for the management of cardiac arrest. the research group is also interested in cpr related injuries and mattress effect. quality of life after ca is evaluated among survivals and the cause of death among non-survivors.


Eligibility criteria:
inclusion criteria: * cardiac arrest * \> 18 years of age exclusion criteria: * \< 18 years of age

Keywords: cpr tissue perfusion invasive arterial pressure exhaled carbon dioxide quality of life quality of chest compressions epidemiology of sudden cardiac arrest(ohca)
upfront surgical resection for osteosarcoma

Conditions: Osteosarcoma

Summary: the goal of this pilot study is to learn about patients with newly diagnosed osteosarcoma of an extremity, and whether surgically removing the tumor prior to the administration of any chemotherapy will improve functional outcomes. in order to learn about the patient's experience, the study team will administer questionnaires to the patient and surgeon at various timepoints to assess recovery and the function of the extremity.

this prospective, non-randomized pilot study will assess patient-reported functional outcomes of upfront surgical resection in patients with newly diagnosed, biopsy-proven, localized osteosarcoma of the extremity or the pelvis. following biopsy, all patients will undergo wide excision of the tumor followed by systemic multi-agent cytotoxic chemotherapy consisting of a regimen at least equivalent to the standard of care of high dose methotrexate, doxorubicin, and cisplatin (map). patients and/or their parent/guardian will be administered promis (patient-reported outcomes measurement information system) questionnaires, while surgeons will be administered the musculoskeletal tumor society (msts) questionnaire at various timepoints through the first year post-surgery.

Eligibility criteria:
inclusion criteria: * patients must have newly diagnosed, previously untreated, localized, high-grade osteosarcoma of an extremity (verified by histopathology) with plans to undergo upfront surgical resection of the tumor followed by systemic chemotherapy. * patients must have a performance status corresponding to eastern cooperative oncology group (ecog) scores of 0, 1, or 2 (karnofsky will be used for patients \>16 years of age and lansky score for patients \<= 16 years of age) exclusion criteria: * patients with metastatic disease at diagnosis * initiation of systemic therapy prior to enrollment * prior history of cancer * prior radiation therapy * active life-threatening infection * pregnancy (negative pregnancy test result must be obtained for female patients of childbearing potential)
extended-release buprenorphine as a novel low-dose induction strategy

Conditions: Opioid Use Disorder

Summary: this is a clinical trial to characterize the safety and pharmacokinetics of using extended-release buprenorphine (xr-bup) as a novel low-dose buprenorphine induction strategy. individuals with a dsm-5 diagnosis of oud (n=30) will be admitted to an inpatient unit to complete study procedures over the course of 5 days. participants will receive fentanyl to prevent the emergence of withdrawal. each participant will then receive a single injection of xr-bup after which study staff will monitor for any precipitated withdrawal.

the approach is to conduct a single ascending dose trial in a controlled human laboratory setting with individuals with a dsm-5 diagnosis of oud (n=30) actively using illicit fentanyl. after obtaining informed consent and establishing eligibility, 10 participants will be scheduled for an inpatient visit lasting 5 days-4 nights and receive xr-bup when not yet experiencing any opioid withdrawal. participants will receive fentanyl to prevent the emergence of withdrawal, and on the following morning, receive xr-bup 16mg in single-blind fashion. if at least 90% successfully complete induction (success defined as experiencing no precipitated withdrawal) with the 16mg dose, then we will proceed with 10 more participants to receive the 24mg dose. if at least 90% successfully complete induction the 24mg dose, then we will proceed with 10 more participants to the 32mg dose. timed blood samples will be collected in heparinized vacutainer tubes via a catheter in the antecubital vein at baseline, and at 0.5, 1, 2, 4, 6, 8, 12, 24, 48 and 72 hours after the xr-bup injection.

Eligibility criteria:
inclusion criteria: * english speaking adults aged 18 and above. * dsm-5 diagnosis of opioid use disorder. * self-reporting use of illicit opioids in \>21 days in the prior 30 days. * provide urine toxicology testing positive for fentanyl at baseline. exclusion criteria: * seeking medication treatment for opioid use disorder with sublingual buprenorphine or methadone. * received buprenorphine or methadone treatment in prior 30 days. * current dsm-5 diagnosis of alcohol or sedative/hypnotic use disorder. * physical dependence on alcohol or sedative/hypnotics. * psychotic disorder, active suicidality or homicidally or any psychiatric condition that impair ability to provide informed consent. * requiring treatment with opioids for acute or chronic pain. * history of hypersensitivity or allergy to buprenorphine or fentanyl. * pregnant or breastfeeding.

Keywords: opioid use disorder buprenorphine
rarc vs lrc in a multicenter cohort study

Conditions: Bladder Cancer

Summary: a multicenter, retrospective research was conducted. patients who underwent robot-assisted radical cystectomy and laparoscopic radical cystectomy in 10 large medical centers in china were enrolled, comparing the oncologic outcomes of the patients.


Eligibility criteria:
inclusion criteria: * \>18 years old; clinical stage ta-t4a/n0-3/m0 exclusion criteria: * severe cardiovascular disease; history of previous major abdominopelvic surgery; patients with distant metastases; medical history of malignancy in other organs.

Keywords: bladder cancer radical cystectomy robot-assisted laparoscopy conventional laparoscopy
application of economics & social psychology to improve opioid prescribing safety trial 1: ehr nudges

Conditions: Opioid Abuse, Unspecified

Summary: the opioid epidemic has had a tremendous negative impact on the health of persons in the u.s. the objective of the trial 1 of application of economics \& social psychology to improve opioid prescribing safety (aesops-t1), is to discourage unnecessary opioid prescribing through the application of "behavioral insights"-empirically-tested social and psychological interventions that affect choice.

a multisite study, aesops-t1 randomizes clinics to behavioral intervention or control. clinics randomized to the behavioral intervention arm receive electronic health record (ehr)-based nudges. eligible participants are clinicians who practice ambulatory primary care at the participating clinical sites in illinois and california. at the time of opioid prescribing, clinicians in clinics randomized to the intervention group will be prompted with an ehr nudge when the prescribing history for the patient falls into one of the following three mutually exclusive categories: opioid naïve, at-risk for long-term use, or long-term opioid recipient. these ehr-based nudges include accountable justification, defaults and precommitments. the control arm receives no ehr-based intervention. both arms receive guideline education. the primary outcome is the change in clinician aggregate weekly milligram morphine equivalent (mme) dose and the secondary outcome is the proportion of dosages that equal or exceed 50 mme per day. these outcomes will be estimated by treatment arm with an intent-to-treat difference-in-differences framework using a mixed-effects regression model on clinician mme daily dose. the intervention period will be 18-months, with a 6-month follow-up period to measure the persistence of effects after the interventions conclude.

Eligibility criteria:
inclusion criteria: * providers of clinics that see patients ≥ 18 years old and for whom clinic leadership agrees to participate. exclusion criteria: * visits will be excluded from intervention when the patient has active cancer.

Keywords: opioid use disorder randomized control trial behavioral economics nudges
a study to assess gw433908 (fosamprenavir) containing regimens in hiv-1 infected subjects

Conditions: Infection, Human Immunodeficiency Virus

Summary: gw433908 (fosamprenavir; fpv)is a pro-drug of amprenavir (apv) which is more water soluble and can be formulated into a tablet with a reduced pill burden (four 700mg tablets of fpv versus sixteen 150mg capsules daily for apv. this study is designed to provide additional information on long term safety and tolerability of fpv containing regimens for those subjects who received fpv in previous glaxosmithkline studies.

viiv healthcare is the new sponsor of this study, and glaxosmithkline is in the process of updating systems to reflect the change in sponsorship.

Eligibility criteria:
inclusion criteria: * male or non-pregnant/non-lactating females \>/=13 years of age (or \>/= 18 years of age according to local requirements). * received fosamprenavir through prior participation in apv20001, apv30002, apv30003 or pro30017 or have participated in apv30001 or other studies as deemed appropriate by the project team. exclusion criteria: * permanent discontinuation of gw433908 in a previous study due to intolerance. * an active cdc class c event. * any condition which, in the opinion of the investigator, would preclude a subject from participation.

Keywords: antiretroviral therapy naive subjects fosamprenavir hiv-1 protease inhibitor pro-drug antiretroviral therapy lexiva agenerase gw433908 amprenavir
pemetrexed and best supportive care versus placebo and best supportive care in non-small cell lung cancer (nsclc)

Conditions: Non-Small Cell Lung Cancer

Summary: this study is a randomized phase 3, double-blind study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care in nsclc. participants must have received 1 of 6 induction regimens for 4 cycles and did not have progressive disease prior to randomization (enrollment) into this trial.


Eligibility criteria:
inclusion criteria: * histologic or cytologic diagnosis of nsclc stage iiib (with pleural effusion and/or positive supraclavicular lymph nodes) or stage iv prior to induction therapy. * participants must have had 1 of the following induction therapies for treatment for stage iiib (with pleural effusion and/or positive supraclavicular lymph nodes) or iv nsclc: gemcitabine plus carboplatin, paclitaxel plus carboplatin, or docetaxel plus carboplatin, gemcitabine plus cisplatin, paclitaxel plus cisplatin or docetaxel plus cisplatin. * participants must have received only 1 chemotherapeutic doublet lasting precisely 4 cycles. * induction regimens must be based on 21-day cycles. * documented evidence of a tumor response of complete response (cr), partial response (pr), or stable disease (sd). tumor assessment must occur between cycle 4 (day 1) of induction therapy and the date of randomization. this response does not have to be confirmed in order for the participant to be randomized. positron emission tomography (pet) scans and ultrasounds may not be used for lesion measurements for response determination. exclusion criteria: * with the exception of those chemotherapies listed as inclusion criterion, participants will not be included if they have received prior systemic anticancer therapy (including adjuvant early-stage treatment for nsclc) or any systemic treatment for any other cancer. * have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry. * inability to comply with protocol or study procedures. * a serious concomitant systemic disorder that would compromise the participant's ability to complete the study. * a serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the new york heart association class iii or iv.
sensing atrial high rate episodes with implantable cardioverter-defibrillators trial (the sense trial)

Conditions: Atrial Fibrillation

Summary: the primary aim of the "sensing atrial high rate episodes with dx system in implantable cardioverter defibrillators trial" (sense trial) is to assess the efficacy of a implantable cardioverter-defibrillator (icd) lead with dedicated atrial sensing dipoles in detecting atrial high rate episodes. the study hypothesis is that an icd system with a lead with dedicated atrial sensing dipoles will have a diagnostic yield comparable to that of a standard dual chamber icd system and superior to that of a standard single chamber icd system.

the sense trial is designed to study the efficacy of the dx system in detection of atrial high rate episodes (ahres) in subjects with no prior history of atrial fibrillation. the dx system, or "dx," consists of a biotronik dx icd, and the biotronik linox smart s dx lead which is an fda approved icd system that incorporates use of an implantable cardioverter-defibrillator (icd) lead with dedicated atrial sensing dipoles. the sense trial will be conducted at 8-12 u.s. sites. the lead coordinating site will be at weill cornell medical college. subjects will be followed for 1 year to assess for the primary endpoints of the trial.

Eligibility criteria:
inclusion criteria: * fulfills standard indications for icd implantation * subject or legally authorized representative can provide written authorization per institutional requirements * subject is intended to be implanted with a complete biotronik dx system (consisting of a biotronik ilesto 7 vr-t dx icd or any future fda approved lumax vr-t dx icd, and the biotronik linox smart s dx lead), or has been implanted with a complete biotronik dx system no more than 30 days prior to the date of consent * able to comply with home monitoring exclusion criteria: * subject has prior diagnosis of atrial fibrillation or atrial flutter * subject has need for atrial pacing * subject unwilling or unable to give informed consent or participate in follow-up * subject is unable to comply with home monitoring * subject is pregnant * subject has less than one year estimated life expectancy * subject was implanted with a cardiac device capable of detecting ahres prior to implantation of the biotronik dx system * subject was implanted with biotronik dx system and had an ahre detection before enrollment

Keywords: atrial fibrillation implantable defibrillators implanted electrodes
evaluation of 1440nm laser vs. botulinum toxin or miradry® microwave for treatment of axillary hyperhidrosis

Conditions: Hyperhidrosis

Summary: the purpose of the study is to evaluate the 1440nm laser assisted selective photothermolysis vs. botulinum toxin or miradry® microwave thermolysis for treatment of axillary hyperhidrosis.


Eligibility criteria:
inclusion criteria: * a healthy non-smoking male or female between 18-70 years of age * understand/accept obligation not to receive any other procedures in anatomical areas exhibiting axillary hyperhidrosis through 3 months prior to treatment * understand and accept the obligation and is logistically able to present for all scheduled follow-up visits * clinically diagnosed for primary hyperhidrosis of the axilla. * a self-assessed hyperhidrosis disease severity scale (hdss) score of three (3) or four (4) a. gravimetric \>50mg/5min in each axilla exclusion criteria: * clinical diagnosis of secondary hyperhidrosis * uncontrolled systemic disease or infection * concurrent use of any hyperhidrosis treatments other than over the counter antiperspirants or deodorants * receipt of botox® or dysport® within the past six months * patients who refuse to stop using over the counter antiperspirants 24 hours prior to the day of surgery and each of the follow-up visits at 3 months and 6 months that minors starch iodine tests may be performed. * patients using or having used within 7 days of baseline visit: cholinomimetic agents, anticholinergic agents, prescription antiperspirants, any herbal medicine treatments or any other treatments for hyperhidrosis except otc antiperspirant or planning to use such agents during the course of the study. * any previous liposuction/liposculpture or any type of surgery for hyperhidrosis; or any other types of treatments for hyperhidrosis in the area to be treated in the past 6 months * has any other medical condition, that, in the investigator's opinion would interfere with the subject's participation in the study * is susceptible to light induced seizures or history of seizures * has a history of keloid formation * significant cardiovascular disease * bleeding disorders * anti-platelet and anticoagulant medication * sensitivity to lidocaine or epinephrine * pregnancy or planned pregnancy * existing neuromuscular disorders (myasthenia gravis, eaton-lambert syndrome, amyotrophic lateral sclerosis) * electronic implants * subjects requiring supplemental oxygen * has therapies or medications which may interfere with the treatment (including medications causing photosensitivity * allergic to keflex